Pfizer offers a substantial 6.6% dividend yield, but its payout ratio exceeds 100%. Eli Lilly has a payout ratio of around 30% but only offers a small 0.6% dividend yield. Merck presents a balanced option with a 3.4% yield and a 45% payout ratio, appealing to long-term income investors.

While Eli Lilly is performing well with GLP-1 weight-loss drugs, its low 0.6% dividend yield may deter income seekers. Pfizer faces challenges with a payout ratio over 100% and upcoming patent expirations. Merck stands out as a middle ground option with a 3.4% dividend yield and a safe payout ratio of around 45%.

Merck offers a reliable 3.4% dividend yield and a manageable 45% payout ratio, making it an attractive choice for dividend investors seeking stability. Despite potential risks from patent expirations, Merck’s financial position is stronger than Pfizer’s, providing more support for its dividend.

Investors considering Merck should acknowledge both the potential risks and rewards. The company faces patent expirations, but strategic acquisitions like Cidara Therapeutics enhance its position. While not the top-performing pharmaceutical company, Merck’s stable dividend and financial strength make it a compelling investment for income seekers.

A $1,000 investment in Merck could provide about 10 shares with substantial and well-supported dividend income. As a reliable high-yield option in the pharmaceutical sector, Merck offers a balanced approach for dividend investors.

Read more at Yahoo Finance: The Ultimate High-Yield Drug Stock to Buy With $1,000 Right Now